Major League Baseball and the Major League Baseball Players Association (MLBPA) have published the annual report of the Joint Drug Prevention and Treatment Program, administered by Dr. Thomas M. Martin. Spanning the beginning of last year’s offseason through the end of this year’s postseason, this report reveals important data on the state of drug testing in the league.
Results of the 2024 Report
During the 2024 reporting period, a total of 11,609 anti-doping tests, the second highest number in the history of the program. This number represents an average of almost 10 tests per year per player on 40-man rosters.
From these tests, 9,455 urine samples were analyzed for performance-enhancing substancesstimulants, DHEA, diuretics, masking agents and recreational drugs. Additionally, 2,154 blood samples were analyzed for the presence of human growth hormone.
Positive Tests
The report notes that two positive tests were found among players on the 40-man rosters, both for performance-enhancing substances. This result is significant, since in the last two testing periods a total of three positive tests have been recorded among players on the 40-man rosters.
These data underline the effectiveness of the program in detecting and preventing the use of prohibited substances.
MLB’s Joint Drug Prevention and Treatment Program is critical to maintaining integrity in baseball. The high number of tests carried out reflects the commitment of the league and the players’ association to ensure clean and fair play.
Dr. Thomas M. Martin, independent administrator of the program, has played a crucial role in the implementation and oversight of these tests, ensuring their transparency and effectiveness.
With an average of almost 10 tests per player and only two positive results, the program demonstrates its effectiveness in the fight against doping.
Meridiano.net
